Lifeloc Q3 2026 Earnings: Revenue Up 12% To $2.522 Million, Loss Narrows

Lifeloc (LCTC) grew Q3 revenue 12% to $2.522 million, narrowing its net loss as gross margins improved. Management is refocusing R&D on core breath alcohol units to boost cash flow while delaying its SpinDetect commercial launch.

Lifeloc Q3 2026 Earnings: Revenue Up 12% To $2.522 Million, Loss Narrows

Lifeloc Technologies (LCTC)' Q3 2026 net revenue rose 12% to $2.522 million and its net loss narrowed to $(85) thousand from $(263) thousand. Gross margin rose to 43%. It now expects SpinDetect's limited launch in Q4 2027.

Ticker: LCTC

Lifeloc Technologies, Inc. (LCTC), which makes breath alcohol and drug testing devices, reported results for the quarter ended September 30, 2026 on November 16. Price increases and a favorable product mix lifted margins, while research and development spending on its SpinDetect drug analyzer remained high and kept the company at a small loss.

The key numbers (third quarter 2026)

Metric

This year

Last year

Change

Net revenue

$2.522 million

$2.257 million

+12%

Gross margin

43%

40%

Research and development

$506 thousand

Net loss

$(85) thousand

$(263) thousand

Diluted EPS

$(0.03)

$(0.10)

Products

The company said its L-series LX9 and LT7 alcohol testing units address needs such as smartphone pairing, wider temperature ranges and customization in local languages, and that its Easycal automated calibration station has helped it gain market share, especially for its workplace Phoenix 6.0 BT and EV 30 devices.

SpinDetect update

Lifeloc has completed the design of the SpinDetect microfluidic disk and will begin beta testing an oral-fluid analyzer focused on delta-9-THC detection under a signed beta-testing agreement. The release states the company now expects the limited commercial launch in Q4 of 2027 rather than Q1 of 2027. It is redirecting part of its engineering resources back to upgrades of its core breath alcohol products, and will run SpinDetect beta testing and validation with current staff.

Balance sheet

Cash and cash equivalents were $930,539 at September 30, 2026, against $746,001 at December 31, 2025.

President and Chief Executive Dr. Wayne Willkomm said: "We are raising the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow." He added that AI tools have reduced the cost and timeline for hardware and firmware upgrades.

Nine months so far

For the first nine months of 2026, net revenue was $7.261 million, against $6.754 million a year earlier, and the net loss narrowed to $(372) thousand, or $(0.14) per diluted share, from $(950) thousand, or $(0.35) per diluted share. Gross margin for the nine months was 44%, against 41%.

Source: SEC Form 8-K Exhibit 99.1

STOCKS IN THIS ARTICLE

Comments